ORBIMED ADVISORS LLC
Q4 2019 13F-HR Holdings
Net value change ($000)
—
New positions
131
Sold out positions
0
Turnover %
100.0%
Sector allocation + QoQ delta (equities-only)
Holdings aggregated across other managers listed in the original SEC filing. View detailed breakdown
Snapshot: Change Analysis
Compared to previous filing: —
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| ASND | 465,092 | — |
| Synthorx, Inc. | 371,560 | — |
| Tricida, Inc. | 362,843 | — |
| SpringWorks Therapeutics, Inc. | 285,069 | — |
| Prevail Therapeutics Inc. | 218,810 | — |
| BSX | 211,394 | — |
| ALEC | 189,322 | — |
| ALXN | 179,809 | — |
| MRK | 177,725 | — |
| Mirati Therapeutics, Inc. | 172,750 | — |
Top Reduces (Value $000, Stocks/ETFs)
| — |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
21,718
(0.3% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|